AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34468248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatments for COPD
Number of subjects: 0
Study 34468248 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis principles
Number of subjects: 0
Study 32730613 — intervention group
Group type: EXPERIMENTAL
Intervention: ENABLE CHF‐PC intervention (in‐person palliative care consultation and 6 weekly nurse‐coach telephonic sessions for 16 weeks)
Number of subjects: 415
Study 32730613 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study 32730613 — intervention group
Group type: EXPERIMENTAL
Intervention: ENABLE CHF‐PC intervention
Number of subjects: 415
Study 33421590 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GMI) training for 6 weeks
Number of subjects: 20
Study 33421590 — intervention group
Group type: COMPARATOR
Intervention: Waiting period (control) for 6 weeks
Number of subjects: 20
Study 32305531 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS procedure
Number of subjects: 0
Study 32305531 — intervention group
Group type: COMPARATOR
Intervention: Two stage hepatectomy (TSH)
Number of subjects: 0
Study 32812324 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN from the adventitia of the renal artery plus adrenalectomy
Number of subjects: 60
Study 32812324 — intervention group
Group type: COMPARATOR
Intervention: Adrenalectomy alone (control group)
Number of subjects: 60
Study 32812324 — intervention group
Group type: EXPERIMENTAL
Intervention: RDN group
Number of subjects: 60
Study 35286195 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate light exposure (100 lx) during sleep
Number of subjects: 0
Study 35286195 — intervention group
Group type: COMPARATOR
Intervention: Dimly lit environment (<3 lx) during sleep
Number of subjects: 0
Study 34852645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐TENS+TOT
Number of subjects: 120
Study 34852645 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni‐TENS+TOT
Number of subjects: 120
Study 32986238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 European Society of Cardiology criteria for HFpEF
Number of subjects: 0
Study 32986238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2016 echocardiographic algorithm for diagnosing diastolic dysfunction
Number of subjects: 0
Study 32986238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2018 evidence‐based H2FPEF score
Number of subjects: 0
Study 32986238 — intervention group
Group type: EXPERIMENTAL
Intervention: 2019 Heart Failure Association HFA‐PEFF algorithm
Number of subjects: 0
Study 35711006 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN)
Number of subjects: 112
Study 35711006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 36041791 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy after 6 months
Number of subjects: 127
Study 36041791 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 127
Study 36041791 — intervention group
Group type: COMPARATOR
Intervention: IgAN patients (treatment naive)
Number of subjects: 127
Study 32088534 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block combined with general anesthesia (E + G)
Number of subjects: 70
Study 32088534 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (G)
Number of subjects: 70
Study 34940841 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer training and use (PRISM system) for 12 months
Number of subjects: 300
Study 33706573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy / Mindfulness Based Stress Reduction intervention
Number of subjects: 55
Study 33706573 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 55
Study 32470562 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg orally three times daily for 2 weeks
Number of subjects: 0
Study 32470562 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0
Study 36297029 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (SP group)
Number of subjects: 39
Study 36297029 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (PB group)
Number of subjects: 39
Study 36297029 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta variations of monocytes
Number of subjects: 39
Study 34213493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal nalbuphine (0.5 mL, 0.8 mg) with 3 mL of heavy (0.5%) hyperbaric bupivacaine
Number of subjects: 60
Study 34213493 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal buprenorphine (0.5 mL, 60 mg) with 3 mL of heavy (0.5%) hyperbaric bupivacaine
Number of subjects: 60
Study 34213493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (nalbuphine and buprenorphine)
Number of subjects: 60
Study 33591979 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA (ivermectin, diethylcarbamazine and albendazole)
Number of subjects: 8918
Study 33591979 — intervention group
Group type: COMPARATOR
Intervention: DA (diethylcarbamazine and albendazole)
Number of subjects: 8918
Study 36342149 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen (HBO) combined with X-ray (2 Gy)
Number of subjects: 0
Study 36342149 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric Oxygen (HBO) (2 Gy)
Number of subjects: 0
Study 36342149 — intervention group
Group type: COMPARATOR
Intervention: X-ray (2 Gy)
Number of subjects: 0
Study 34384597 — intervention group
Group type: COMPARATOR
Intervention: Control group (NSS 20 mL before skin incision and at 3 hours after surgery)
Number of subjects: 90
Study 34384597 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dose (1D) group (750 mg TXA before skin incision and NSS 20 mL at 3 hours after surgery)
Number of subjects: 90
Study 34384597 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose (2D) group (750 mg TXA before skin incision and 750 mg TXA at 3 hours after surgery)
Number of subjects: 90
Study 32942770 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized Anxiety Disorder (GAD)
Number of subjects: 220
Study 32942770 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐Traumatic Stress Disorder (PTSD)
Number of subjects: 220
Study 32942770 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 220
Study 32942770 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with MDD
Number of subjects: 220
Study 32942770 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with PTSD
Number of subjects: 220
Study 35121029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on LASSO-Cox model
Number of subjects: 495
Study 34541479 — intervention group
Group type: EXPERIMENTAL
Intervention: ALRV5XR treatment
Number of subjects: 46
Study 34541479 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study 35751704 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Clearfil Flow FX)
Number of subjects: 19
Study 35751704 — intervention group
Group type: COMPARATOR
Intervention: Conventional resin composite (Clearfil AP‐X)
Number of subjects: 19
Study 32505177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg·kg‐1 for 10 min IV, followed by 0.5 μg·kg‐1·h‐1 throughout procedure)
Number of subjects: 60
Study 32505177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 32505177 — intervention group
Group type: COMPARATOR
Intervention: Control (saline at identical velocity as Dex group)
Number of subjects: 60
Study 35679842 — intervention group
Group type: EXPERIMENTAL
Intervention: PNAC
Number of subjects: 174
Study 35679842 — intervention group
Group type: COMPARATOR
Intervention: No PNAC
Number of subjects: 174
Study 34015364 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral contigs identified through sequencing
Number of subjects: 2
Study 34015364 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of Mansoniini viruses
Number of subjects: 2
Study 32216814 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3008348 (1000 mcg nebulised dose)
Number of subjects: 8
Study 32216814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 34641800 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling group (n=40)
Number of subjects: 80
Study 34641800 — intervention group
Group type: COMPARATOR
Intervention: Non-swaddling group (n=40)
Number of subjects: 80
Study 34325518 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (measured by Apnea-Hypopnea Index, AHI)
Number of subjects: 94
Study 34325518 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive AHI
Number of subjects: 94
Study 34325518 — intervention group
Group type: EXPERIMENTAL
Intervention: Central AHI
Number of subjects: 94
Study 35256054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic resistance training (12-week supervised, progressive)
Number of subjects: 90
Study 35256054 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive during dialysis)
Number of subjects: 90
Study 33492871 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior iliopsoas muscle space block
Number of subjects: 48
Study 33492871 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar plexus block
Number of subjects: 48
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard BW treatment with 12L:12D rearing photoschedule
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: High BW treatment
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: 8L:16D rearing photoschedule
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: 10L:14D rearing photoschedule
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: 12L:12D rearing photoschedule
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: Model IV
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: Model I
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: ME requirement for ADG
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: ME requirement for EM
Number of subjects: 180
Study 32867986 — intervention group
Group type: EXPERIMENTAL
Intervention: Models II-IV
Number of subjects: 180
Study 35795456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraditional guitar instruction
Number of subjects: 26
Study 35795456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontraditional guitar instruction (Group 1 exposed to intervention first)
Number of subjects: 26
Study 32249746 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (universal prevention program)
Number of subjects: 308
Study 32249746 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 308
Study 36482616 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term electrocardiogram (ECG) screening for atrial fibrillation (AF)
Number of subjects: 89
Study 36482616 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 89
Study 33749643 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg/day) + DHA (800 mg/day)
Number of subjects: 160
Study 33749643 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg/day)
Number of subjects: 160
Study 33749643 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (800 mg/day)
Number of subjects: 160
Study 33749643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 32855064 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35752776 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity mannequin training
Number of subjects: 28
Study 35752776 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity mannequin training
Number of subjects: 28
Study 32725783 — intervention group
Group type: EXPERIMENTAL
Intervention: AP30663
Number of subjects: 47
Study 35212621 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered intervention by Peer Navigators
Number of subjects: 68
Study 32220771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol plus hypertonic saline combination (MHS)
Number of subjects: 326
Study 32220771 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline monotherapy (HS)
Number of subjects: 326
Study 35984626 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 200 mg/2 mL subcutaneous injection of tildrakizumab
Number of subjects: 0
Study 35984626 — intervention group
Group type: COMPARATOR
Intervention: Two 100 mg/1 mL subcutaneous injections of tildrakizumab
Number of subjects: 0
Study 32980245 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based economic intervention
Number of subjects: 358
Study 34365016 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of in-person group sessions plus 11 months of eHealth communication
Number of subjects: 241
Study 34365016 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person group sessions alone
Number of subjects: 241
Study 34365016 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth alone
Number of subjects: 241
Study 34365016 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 241
Study 32727304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment
Number of subjects: 5
Study 32727304 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 5
Study 32727304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of malnutrition after six months
Number of subjects: 5
Study 32130136 — intervention group
Group type: EXPERIMENTAL
Intervention: SNI-TP (Social Networking Intervention with Time Pressure)
Number of subjects: 205
Study 32130136 — intervention group
Group type: EXPERIMENTAL
Intervention: SNI+TP (Social Networking Intervention without Time Pressure)
Number of subjects: 205
Study 32130136 — intervention group
Group type: EXPERIMENTAL
Intervention: SNI+TP
Number of subjects: 205
Study 32130136 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 205
Study 32130136 — intervention group
Group type: EXPERIMENTAL
Intervention: SNI-TP
Number of subjects: 205
Study 32130136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups
Number of subjects: 205
Study 34752667 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 10% nail lacquer
Number of subjects: 953
Study 34752667 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 953
Study 34752667 — intervention group
Group type: EXPERIMENTAL
Intervention: Amorolfine 5%
Number of subjects: 953
Study 35991113 — intervention group
Group type: EXPERIMENTAL
Intervention: History first (HF)
Number of subjects: 52
Study 35991113 — intervention group
Group type: COMPARATOR
Intervention: EKG first (EKGF)
Number of subjects: 52
Study 36405443 — intervention group
Group type: EXPERIMENTAL
Intervention: Flanged intrascleral IOL fixation using the Yamane technique (Group A)
Number of subjects: 35
Study 36405443 — intervention group
Group type: COMPARATOR
Intervention: 4-point transscleral fixation of IOL using Gore-Tex suture (Group B)
Number of subjects: 35
Study 33145441 — intervention group
Group type: EXPERIMENTAL
Intervention: myCOPD app
Number of subjects: 41
Study 33145441 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 41
Study 34968002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection
Number of subjects: 77
Study 34968002 — intervention group
Group type: COMPARATOR
Intervention: Prosection
Number of subjects: 77
Study 32698986 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated securement dressing
Number of subjects: 109
Study 32698986 — intervention group
Group type: COMPARATOR
Intervention: Simple polyurethane dressing
Number of subjects: 109
Study 32513289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 400 μg/kg
Number of subjects: 24
Study 32513289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34932192 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel drug candidate for nocturnal polyuria
Number of subjects: 302
Study 32753750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling therapy
Number of subjects: 45
Study 32753750 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45
Study 34991562 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 130
Study 34991562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 130
Study 33740113 — intervention group
Group type: EXPERIMENTAL
Intervention: glasdegib + low-dose cytarabine (LDAC)
Number of subjects: 96
Study 32130166 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based support intervention
Number of subjects: 1000
Study 32130166 — intervention group
Group type: COMPARATOR
Intervention: Standard postabortion family planning care
Number of subjects: 1000
Study 36273386 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 842
Study 33035103 — intervention group
Group type: COMPARATOR
Intervention: Mechanical thromboprophylaxis only (group A)
Number of subjects: 150
Study 33035103 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mechanical and chemical thromboprophylaxis (group B)
Number of subjects: 150
Study 35559512 — intervention group
Group type: EXPERIMENTAL
Intervention: COX inhibition (10 mM ketorolac)
Number of subjects: 5
Study 35559512 — intervention group
Group type: EXPERIMENTAL
Intervention: EDHF inhibition (50 mM tetraethylammonium, TEA)
Number of subjects: 5
Study 35559512 — intervention group
Group type: COMPARATOR
Intervention: Control (lactated Ringer's)
Number of subjects: 5
Study 32115341 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (early and intense lower extremity training using a recumbent cycle ergometer)
Number of subjects: 31
Study 32115341 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 31
Study 32115341 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 31
Study 32115341 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 33885348 — intervention group
Group type: EXPERIMENTAL
Intervention: English intervention program
Number of subjects: 124
Study 33885348 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 124
Study 36074476 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal-flow LVAD (HeartMate 3)
Number of subjects: 295
Study 36074476 — intervention group
Group type: COMPARATOR
Intervention: Axial-flow LVAD (HeartMate II)
Number of subjects: 295
Study 35778255 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person abortion video stories (n = 460)
Number of subjects: 886
Study 35778255 — intervention group
Group type: COMPARATOR
Intervention: Nature videos (n = 426)
Number of subjects: 886
Study 33828182 — intervention group
Group type: EXPERIMENTAL
Intervention: summary data‐based MR (SMR) method
Number of subjects: 0
Study 33828182 — intervention group
Group type: EXPERIMENTAL
Intervention: MR Steiger method
Number of subjects: 0
Study 33828182 — intervention group
Group type: EXPERIMENTAL
Intervention: simple and yet more powerful alternative to SMR
Number of subjects: 0
Study 35100785 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pediatric CPR
Number of subjects: 21
Study 35100785 — intervention group
Group type: COMPARATOR
Intervention: Walking pediatric CPR
Number of subjects: 21
Study 32484630 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA 2x
Number of subjects: 166
Study 32484630 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA 3x
Number of subjects: 166
Study 32484630 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (VEH) pooled (VEH 2x + VEH 3x)
Number of subjects: 166
Study 32173802 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg 30 minutes before induction
Number of subjects: 60
Study 32173802 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiological saline)
Number of subjects: 60
Study 33927086 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/emtricitabine + dolutegravir (TAF/FTC + DTG)
Number of subjects: 1053
Study 33927086 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate/FTC + dolutegravir (TDF/FTC + DTG)
Number of subjects: 1053
Study 33927086 — intervention group
Group type: COMPARATOR
Intervention: tenofovir disoproxil fumarate/FTC + efavirenz (TDF/FTC/EFV)
Number of subjects: 1053
Study 33081758 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing oxytocin during the active phase of labor
Number of subjects: 2475
Study 33081758 — intervention group
Group type: COMPARATOR
Intervention: Continuing oxytocin infusion
Number of subjects: 2475
Study 36102339 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training (2-hour virtual training)
Number of subjects: 15
Study 34776918 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized reaching practice
Number of subjects: 0
Study 34776918 — intervention group
Group type: EXPERIMENTAL
Intervention: First-order model with a constant learning rate
Number of subjects: 0
Study 34776918 — intervention group
Group type: EXPERIMENTAL
Intervention: Practiced movement direction
Number of subjects: 0
Study 34776918 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpracticed movement directions
Number of subjects: 0
Study 36068554 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Renal Replacement Therapy (CRRT)
Number of subjects: 2542
Study 36068554 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Hemodialysis (IHD)
Number of subjects: 2542
Study 36068554 — intervention group
Group type: EXPERIMENTAL
Intervention: ATN treatment protocol (among CRRT-first patients)
Number of subjects: 2542
Study 36191321 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study 36191321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33582525 — intervention group
Group type: EXPERIMENTAL
Intervention: active cTBS
Number of subjects: 33
Study 33582525 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 33
Study 32874106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) - computerized exercise program, 3 times per week for 6 weeks
Number of subjects: 44